moonlaketx.com (MLTX) - Market Value to Book Value Ratio

MoonLake Immunotherapeutics AG (MLTX) - corporate logo

The linear price action on the MoonLake Immunotherapeutics (MLTX) chart reflects the asset's quotes, with a value of 2.41. MoonLake Immunotherapeutics focuses on developing advanced nanobodies, investing in sonelokimab to combat severe inflammation. Growth potential is based on exclusive therapy rights, which promise high profits. To mitigate single-product risk, the business is expanding the drug's application within rheumatology and dermatology.

MoonLake Corp (MLTX) - Market Value to Book Value from 04/28/2023 to 10/29/2026

MoonLake Immunotherapeutics AG (MLTX) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Stock Quotes MoonLake Immunotherapeutics|MLTX - Broker Consensus Forecast
- market capitalization indicators:
Market Value MoonLake Pharma|MLTX - Full Business Value
- book capitalization data:
Book Value per Share MoonLake Immunotherapeutics|MLTX - Accounting Value of Company|Market Capitalization to Book Value Ratio moonlaketx.com|MLTX - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Equity MoonLake Immunotherapeutics|MLTX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MoonLake Pharma|MLTX - Company Total Debt|Debts to Book Capitalization MoonLake Pharma|MLTX - Company Long-Term Debts|Company Current Liabilities MoonLake Immunotherapeutics|Quick Liquidity moonlaketx.com
- earnings and valuation multiples indicators:
MLTX - Net Income
Basic company analysis:MoonLake Immunotherapeutics - MLTX
Manufactured product of MoonLake Pharma

MoonLake Immunotherapeutics focuses on developing breakthrough immunological drugs, where the primary capital is concentrated in intellectual property and clinical development. The price-to-book value ratio trend demonstrates a market premium over net assets, measuring investor expectations regarding the future capitalization of management's innovations. High indicator values confirm market confidence in the success of trials, although they necessitate monitoring the risk of asset overvaluation.

Competitor analysis

ASND (Ascendis Pharma A/S) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio MDGL|Market Value to Book Value Ratio Corcept Therapeutics Incorporated|Rhythm Pharma - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio AKRO|MTSR (Metsera Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio CRNX (Crinetics Pharmaceuticals)|Market Capitalization to Book Value Ratio newamsterdampharma.com NAMS|SLNO - Market Value to Book Value Ratio|Market Value to Book Value FOLD (Amicus Therapeutics Inc)|89bio Corp (ETNB) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Agios Corp|GPCR (Structure Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio mimedx.com|Market Cap to Net Assets Ratio RZLT (Rezolute)|LXRX (Lexicon Pharmaceuticals Inc) - Market Value to Book Value|Market Value to Book Value Ratio MBX Bio MBX|ALT - Market Cap to Net Assets Ratio|Aardvark Therapeutics Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio sagimet.com|BIOA (BioAge) - Market Cap to Net Assets Ratio|BMEA: Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio VTVT|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|Market Value to Book Value Ratio Pluri PLUR|Synlogic Inc. (SYBX) - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB: Market Value to Book Value Ratio|SPRB: Market Capitalization to Book Value Ratio|GLTO - Market Capitalization to Book Value|Market Value to Book Value Ratio Carmell|Lumos Pharma Inc (LUMO) - Market Capitalization to Book Value|Market Value to Book Value Ratio Organovo Holdings Inc (ONVO)|Market Cap to Net Assets Ratio Radius Pharmaceuticals RDUS